Sat, May 24, 2025
Fri, May 23, 2025
Thu, May 22, 2025
Wed, May 21, 2025
Tue, May 20, 2025
[ Last Tuesday ] - 13abc
Moment of Science: Cicadas
Mon, May 19, 2025
Sun, May 18, 2025
Sat, May 17, 2025
Fri, May 16, 2025
Thu, May 15, 2025
Wed, May 14, 2025
Tue, May 13, 2025
[ Tue, May 13th ] - WSAZ
Summer science experiments
Mon, May 12, 2025
Sun, May 11, 2025
Sat, May 10, 2025
Fri, May 9, 2025
Thu, May 8, 2025
Wed, May 7, 2025
Tue, May 6, 2025
Mon, May 5, 2025
Sun, May 4, 2025

GSK drug's new approval sets up competition with Dupixent


Published on 2025-05-24 07:02:19 - STAT
  Print publication without navigation

  • And more biotech news brought to you by The Readout.

The article from STAT News dated May 23, 2025, discusses several significant developments in the biotech industry. Novo Nordisk and GSK have announced a collaboration to develop new treatments for obesity and diabetes, leveraging GSK's expertise in respiratory diseases. CRISPR Therapeutics has made strides in its prime editing technology, showing promising results in treating genetic disorders. Additionally, a new COPD treatment from Merus has shown efficacy in clinical trials, potentially offering a new option for patients. Lastly, Merck's Keytruda has been approved for use in combination with other therapies for certain types of cancer, expanding its application in oncology. These updates highlight the ongoing innovation and partnerships driving advancements in healthcare.

Read the Full STAT Article at:
[ https://www.statnews.com/2025/05/23/biotech-news-novo-gsk-crispr-prime-copd-merus-keytruda-cancer-the-readout/ ]

Publication Contributing Sources